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•	 Expression of PD-1 and 
its Ligands, PD-L1 and 
PD-L2, in Smokers and 
Never Smokers with KRAS 
Mutant Lung Cancer
those with more pack-years. Positive PD-L2 expression 
was found in 47% of the patients, not associated 
with smoking status. The presence of PD-1+ tumor 
inﬁltrating lymphocytes was observed in 68% of 114 
tumor specimens analyzed, including 21/27 PD-L1 
positive and 39/54 PD-L2 positive samples. There was a 
signiﬁcant correlation between the age of the specimens 
used for analyses >3 years and fading PD-L1 expression 
(p=0.016). In summary, the ﬁndings demonstrated 
heterogeneity of PD-1, PD-L1 and PD-L2 expressions 
in the KRAS-mutant lung adenocarcinoma, which should 
be taken into account in analysis of clinical outcomes 
from anti-PD-1/PD-L1 therapies. The correlation of 
PD-L1 expression with smoking status but independent 
of speciﬁc KRAS mutations indicates that PD-L1 
expression is inducible by smoking instead of being 
genetically driven by KRAS mutations. The authors 
recommended using an immune diagnostic panel for 
clinical samples of lung cancer and using contemporary 
biopsies for analysis of PD-1 inhibitor treatment in 
NSCLC. (p. 1726)
•	 EGFR Mutation Impact 
on Definitive Concurrent 
Chemoradiation Therapy 
for Inoperable Stage III 
Adenocarcinoma
median progression-free survival (PFS; 9.8 vs. 16.5 
months; p=0.041), lower 2-year recurrence-free survival 
rate (7.7% vs. 28.1%; p=0.028), higher incidence of 
distant metastases at ﬁrst recurrence (76% vs. 40%; 
p=0.001), and less frequent locoregional recurrence 
(14% vs. 35%; p=0.027). No signiﬁcant difference was 
observed between the groups in overall response rate 
(72.4% vs. 72.0%; p=0.607) and overall survival (OS; 
51.1 vs. 42.9 months; p=0.637). The brain was the most 
commonly affected site in EGFR-mutant patients (35%). 
Patients with wild-type EGFR and KRAS mutations had 
signiﬁcantly worse OS vs. those with wild-type EGFR 
and wild-type KRAS (21.6 vs. 49.8 months; p=0.024). 
Taken together, concurrent CRT led to shorter PFS in 
patients with EGFR-mutant versus wild-type stage III 
lung adenocarcinoma, primarily as a result of distant 
metastasis relapse. The ﬁndings suggest alternative 
approaches such as EGFR-TKI therapy for the EGFR-
mutant cohort receiving deﬁnitive CRT. (p. 1720)
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Given clinical responses to PD-1/PD-L1 antibodies in non-small 
cell lung cancer (NSCLC) may be correlated with PD-L1 expression 
and smoking status, the authors in this study retrospectively 
evaluated the expression of PD-1, PD-L1 and PD-L2 in 84 smokers 
and 30 never-smokers with KRAS-mutant NSCLC. Of 114 patients, 
24% patients demonstrated PD-L1 expression, associating with 
smoking status (current smokers 44%, former smokers 20%, never-
smokers 13%; p=0.03), with higher PD-L1 levels in smokers and 
The retrospective analysis included 104 patients with unresectable 
stage III lung adenocarcinoma, who had deﬁnitive concurrent 
chemoradiation therapy (CRT) with ﬁrst-line platinum doublet 
chemotherapy, to assess the effect of EGFR mutation on clinical 
outcomes and recurrence patterns. EGFR mutation was identiﬁed 
in 28% of patients. When compared with wild-type patients 
receiving concurrent CRT, the EGFR-mutant group had worse 
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and maximum standardized uptake value (SUVmax) 
were measured for CT and PET, respectively. After a 
median follow-up of 3.8 years, the results demonstrated 
recurrence in 19% of patients and metastasis in 23% 
following surgery. Pathologic assessment revealed the 
following histologic subtypes: AIS (4.8%), MIA (4.7%), 
lepidic-predominant (17.3%), acinar-predominant 
(43.4%), papillary-predominant (9.0%), micropapillary-
predominant (3.2%), solid-predominant (15.6%), and 
variant adenocarcinomas (1.9%). Signiﬁcantly different 
overall survival (OS) and disease-free survival rates 
were observed based on TDR on CT, SUVmax on PET, 
predominant subtypes, and pattern groups. Multivariate 
analysis showed the SUVmax, TDR, and pattern group 
(P<0.001, P=0.038, and P = 0.015, respectively) as 
independent predictors of OS. Taken together, the ﬁndings 
suggest the prognostic signiﬁcance of TDR on CT, 
SUVmax on PET, and the new histologic classiﬁcation 
schemes for lung cancer patient stratiﬁcation for further 
staging workup and adjuvant treatment. (p. 1785)
•	 Role of CT and PET 
Imaging in Predicting 
Tumor Recurrence and 
Survival in Patients with 
Lung Adenocarcinoma: 
A Comparison with the 
International Association 
for the Study of Lung 
Cancer/American 
Thoracic Society/European 
Respiratory Society 
Classification of Lung 
Adenocarcinoma
The authors reviewed pathologic specimens and imaging 
characteristics of primary tumors of 723 consecutive patients with 
resected lung adenocarcinoma to compare the prognostic value of 
computed tomography (CT) and positron emission tomography (PET) 
with the new lung adenocarcinoma classiﬁcation by IASLC/ATC/
ERS. Analysis of pathology assessed the predominant histologic 
subtype and pattern group. Tumor-shadow disappearance ratio (TDR) 
RESEARCH WATCH
•	 Prognostic Score of 
Long-Term Survival After 
Surgery for Malignant 
Pleural Mesothelioma: A 
Multicenter Analysis
no history of asbestos exposure, and the ratio between 
metastatic and resected lymph nodes < 22% to associate 
most strongly with LTS (odds ratio: 0.51, 7.07, 3.13, 
and 4.12, respectively). A prognostic scoring system 
was developed for LTS to differentiate between patients 
with favorable prognosis and those with poor prognosis 
(area under the curve, 0.74; standard error, 0.04; p < 
0.0001), by correctly predicting overall, cancer-speciﬁc, 
and disease-free survival in the total sample. In summary, 
the novel prognostic model allows the prediction of LTS 
following surgery for patients with MPM, facilitating 
stratiﬁcation of patient for postoperative treatment.
Leuzzi G, Rea F, Spaggiari L, et al. Prognostic Score 
of Long-Term Survival After Surgery for Malignant 
Pleural Mesothelioma: A Multicenter Analysis. The 
Annals of Thoracic Surgery 2015;100:890-897.
The authors developed a statistical model to predict which patients 
would most likely experience long-term survival (LTS; survival 
> 3 years) from extrapleural pneumonectomy for treatment of 
malignant pleural mesothelioma (MPM). A retrospective analysis 
of clinicopathologic and oncological factors was conducted in a 
multicenter cohort of 468 MPM patients receiving extrapleural 
pneumonectomy. The results showed a 22.9% of patients who 
survived at least 3 years, a median overall survival time of 60 months, 
cancer-speciﬁc survival time of 63 months, and disease-free survival 
time of 49 months. The study identiﬁed age, epithelioid histology, 
to afatinib of the patient analyzed in this report. 
Re-sequencing of the tumor from this patient upon 
disease progression discovered an EGFR-dependent 
mechanism of acquired resistance to afatinib, indicating 
EGFR-KDD as a driver alteration and therapeutic target. 
In summary, the identiﬁcation of the oncogenic and drug 
sensitive EGFR-KDD in a patient with advanced lung 
cancer that responded to afatinib could be immediately 
translated to the clinic where several approved EGFR 
inhibitors are in use.
Gallant JN, Sheehan JH, Shaver TM, et al. 
EGFR kinase domain duplication (EGFR-KDD) 
is a novel oncogenic driver in lung cancer that is 
clinically responsive to afatinib. Cancer Discov, 
doi:10.1158/2159-8290.cd-15-0654 (2015).
•	 EGFR Kinase Domain 
Duplication (EGFR-KDD) 
is a Novel Oncogenic 
Driver in Lung Cancer that 
is Clinically Responsive to 
Afatinib
Analysis of the tumor from a 33 year-old male never smoker 
with metastatic lung adenocarcinoma uncovered a novel EGFR 
alteration, the EGFR exon 18-25 kinase domain duplication 
(EGFR-KDD). Recurrent EGFR-KDD was found in lung, brain, 
and soft tissue cancers in a larger cohort of tumor samples. In vitro 
studies demonstrated that EGFR-KDD is constitutively active. 
Computational models revealed potential mechanism of its auto-
activation. Cells transformed with EGFR-KDD showed sensitivity 
to EGFR TKIs, which correlated with the partial response 
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•	 RAS-MAPK Dependence 
Underlies a Rational 
Polytherapy Strategy in 
EML4-ALK–Positive Lung 
Cancer
increase in copy number of the KRAS wild-type gene, 
or downregulated expression of the MAPK phosphatase 
DUSP6. Preclinical studies also demonstrated enhanced 
magnitude and duration of the initial response with 
upfront inhibition of both ALK and MEK in EML4-
ALK lung adenocarcinoma. Taken together, the 
preliminary ﬁndings suggest RAS-MAPK dependence 
in EML4-ALK positive lung adenocarcinoma, 
supporting upfront co-targeting of ALK and MEK to 
suppress resistance and improve outcomes from ALK 
inhibitor treatment.
Hrustanovic G, Olivas V, Pazarentzos E, et al. RAS-
MAPK dependence underlies a rational polytherapy 
strategy in EML4-ALK-positive lung cancer. Nat Med 
2015;21:1038-1047.
This study reported that the GTPase RAS–mitogen-activated 
protein kinase (MAPK) pathway is necessary for tumor cell 
survival in preclinical models of lung adenocarcinoma harboring 
EML4-ALK. All 3 major RAS isoforms were involved in EML4-
ALK mediated RAS-MAPK signaling via the HELP domain of 
EML4. MAPK pathway reactivation led to resistance to ALK 
inhibitors in EML4-ALK positive lung adenocarcinomas. In vitro 
analysis showed that mechanism underlying the reactivation was 
but the nivolumab arm had higher PFS rate at 1 year 
(19% vs. 8%). Greater efﬁcacy across all end points in 
subgroups with ≥1%, ≥5%, and ≥10% tumor-membrane 
PD-L1 expression was observed in the nivolumab arm 
versus the docetaxel arm. Treatment-related grade 3 
or 4 toxicities occurred in 10% of the nivolumab arm 
versus 54% in the docetaxel arm. All in all, the ﬁndings 
suggest that, when compared with docetaxel, nivolumab 
prolongs overall survival of patients with advanced 
nonsquamous NSCLC that progressed on or after 
platinum-based chemotherapy, with almost doubled 
median overall survival in patients with PD-L1-positive 
tumors.
Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab 
versus Docetaxel in Advanced Nonsquamous 
Non–Small-Cell Lung Cancer. NEJM, doi:10.1056/
NEJMoa1507643 (2015).
•	 Nivolumab Versus 
Docetaxel in Advanced 
Nonsquamous Non–Small-
Cell Lung Cancer
In this phase III study, 582 patients with stage IIIB/IV or recurrent 
nonsquamous NSCLC whose disease progressed during or 
after platinum-based doublet chemotherapy were randomized 
to nivolumab or docetaxel. The data demonstrated outcome and 
survival in favor of the nivolumab arm versus the docetaxel arm: 
median overall survival was 12.2 moths vs. 9.4 months (hazard ratio 
[HR] for death, 0.73; P=0.002); 1-year overall survival rate was 
51% vs. 39% (39% vs. 23% at 18 months); response rate was 19% 
vs. 12% (P=0.02). Nivolumab did not prolong median progression-
free survival (PFS) compared with docetaxel (2.3 vs. 4.2 months) 
•	 Randomized Trial of 
Reduced-Nicotine 
Standards for Cigarettes
versus those randomized to their usual brand or 
cigarettes with 15.8 mg/g (22.2 and 21.3 cigarettes, 
respectively; P<0.001). The primary outcome from 
the group assigned to 5.2 mg/g cigarettes did not differ 
signiﬁcantly from the control group, with an average 
of 20.8 cigarettes/day. The data also demonstrated that 
cigarettes with reduced nicotine lowered exposure and 
dependence on nicotine versus the control cigarettes, 
and suppressed craving during abstinence, with minimal 
compensation. Generally mild and similar adverse 
events were observed between groups. In summary, 
this 6-week study suggests that the use of reduced-
nicotine cigarettes could lower nicotine exposure and 
dependence, and the number of cigarettes smoked.
Donny EC, Denlinger RL, Tidey JW, et al. 
Randomized Trial of Reduced-Nicotine Standards for 
Cigarettes. NEJM 2015;373:1340-1349.
This double-blind, parallel, randomized clinical trial aimed to 
assess the impact of cigarettes with reduced nicotine content (from 
15.8 mg to 0.4 mg per gram of tobacco) and those of participants’ 
usual brands for 6 weeks. Eligible participants were ≤18 years old, 
smoking ≥5 cigarettes/day, and not currently interested in quitting 
smoking. Of the 780 participants who completed the 6-week study, 
those who were randomized to cigarettes with 2.4, 1.3, or 0.4 mg 
nicotine/g tobacco had lower average number of cigarettes per 
day during week 6 (16.5, 16.3, and 14.9 cigarettes, respectively) 
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medical cost accounted for US$0.37 billion. Disease 
that scored the highest direct healthcare cost was CVD, 
followed by COPD and other respiratory diseases. The 
total cost of smoking represented 0.78% of the national 
gross domestic product and about 18.19% of total health 
expenditure. In summary, the total economic loss as a 
result of smoking-related diseases has signiﬁcant impact 
on the society, health sector and national economy. The 
ﬁndings could serve to guide national public health 
policy.
Bundhamcharoen K, Aungkulanon S, Makka N, 
Shibuya K. Economic burden from smoking-related 
diseases in Thailand. Tobacco control, doi:10.1136/
tobaccocontrol-2015-052319 (2015).
•	 Economic Burden from 
Smoking-Related Diseases 
in Thailand
NEWS IN BRIEF
•	 FDA Grants 
Accelerated Approval 
to Pembrolizumab for 
Advanced NSCLC
Accelerated approval has been granted by the FDA 
to pembrolizumab for patients with metastatic non-
small cell lung cancer (NSCLC) that progressed after 
platinum-based chemotherapy or targeted therapy, and 
whose tumors expressing programmed cell death-ligand 
1 (PD-L1). The use of pembrolizumab was approved in 
conjunction with a companion diagnostic ﬁrst developed 
for PD-L1 expression detection in NSCLC, the PD-L1 
IHC 22C3 pharmDx test. The approval was based on 
the study demonstrating an overall response rate of 
41% in patients treated with pembrolizumab, which 
lasted between 2.1 and 9.1 months. Fatigue, decreased 
appetite, dyspnea, and cough were the most common 
side effects. Pembrolizumab is also likely to cause 
severe immune-mediated side effects.
Image source: NIH
The authors set out to conduct a prevalence-based, disease-speciﬁc 
cost of illness study to assess the economic burden, including direct 
and indirect medical costs, and productivity loss as a result of 
smoking-related diseases in Thailand in 2009. Seven disease groups 
were included in cost analysis: lung cancer, chronic obstructive 
pulmonary disease (COPD), cardiovascular disease (CVD), upper 
aerodigestive tract cancer, other cancer, other respiratory diseases 
and other medical conditions. The results demonstrated a total of 
US$2.18 billion in economic burden of smoking, most of which 
was attributable to productivity loss at US$1.81 billion. Total 
central review and investigator assessment were similar: 
11.0 vs. 3.9 months (P<0.001), and 14.0 vs. 5.5 months 
(P<0.001), respectively. Central review of everolimus 
vs. placebo demonstrated an ORR (all partial responses) 
of 2% vs. 1%, DCR of 82% vs. 65%, and progressive 
disease in 9% vs. 27%, respectively. An HR of 0.64 
(P=0.037) was achieved in favor of everolimus in a 
pre-planned interim analysis. Grade 1/2 adverse events 
were common, including stomatitis, diarrhea, peripheral 
edema, fatigue, and rash. Most frequent grade 3/4 
toxicities were diarrhea, stomatitis, abdominal pain and 
anemia. Taken together, this large study showed efﬁcacy 
of everolimus in patients with advanced lung/GI NET, 
with a statistically signiﬁcant 52% risk reduction and a 
7.1-month improvement of PFS, alongside with a well-
tolerated safety proﬁle.
•	 ECC 2015: Everolimus in 
Advanced Nonfunctional 
Neuroendocrine 
Tumors (NET) of Lung 
or Gastrointestinal (GI) 
Origin: Efficacy and 
Safety Results from the 
Placebo-Controlled, 
Double-Blind, Multicenter, 
Phase 3 RADIANT-4 Study 
(Abstract 5LBA)
The phase III study assessed mammalian target of rapamycin 
inhibitor, everolimus, versus placebo in 302 patients with advanced 
lung/GI NET, stratiﬁed by tumor origin, WHO performance status, 
and prior somatostatin analogue therapy. Median progression-free 
survival (PFS) in patients treated with everolimus vs. placebo by 
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•	 ECC 2015: A Phase II 
Trial of Erlotinib (E) and 
Bevacizumab (B) in Patients 
with Advanced Non-
Small-Cell Lung Cancer 
(NSCLC) with Activating 
Epidermal Growth Factor 
Receptor (EGFR) Mutations 
with and without T790M 
Mutation. The Spanish Lung 
Cancer Group (SLCG) and 
the European Thoracic 
Oncology Platform (ETOP) 
BELIEF trial (Abstract 3BA)
The authors evaluated ﬁrst line erlotinib in combination 
with bevacizumab in 109 EGFR mutant NSCLC patients 
with and without pre-treatment T790M. Forty-seven 
patients (T790M mutated = 27, non-mutated = 20) remain 
on treatment after a median follow-up of 12 months. 
The results showed that T790M mutated patients were 
of 67 years of age (median), 63% female, 70% never 
smokers and 97% with performance status 0-1, while 
T790M non-mutated patients were of 63 years of age 
(median), 59% female, 61% never smokers and 90% with 
performance status 0-1. The one-year PFS rate for overall 
study population was 55.6%, with a median of 13.6 months 
while T790M mutated patients achieved a one-year PFS of 
60.2%, with a median of 15.4 months. At least one serious 
adverse event was observed in 16 mutated patients and 
11 non-mutated patients. Most common adverse events 
were pancreatitis, confusion and dehydration (T790M 
mutant patients) and thromboembolic event (non-mutated 
patients). In summary, the ﬁndings indicate efﬁcacy 
from the combination of erlotinib and bevacizumab, with 
manageable safety proﬁle in overall and T790M mutated 
patients.
•	 ECC 2015: Safety, Activity, 
and Response Durability 
Assessment of Single Agent 
Rovalpituzumab Tesirine, 
a Delta-Like Protein 3 
(DLL3)-Targeted Antibody 
Drug Conjugate (ADC), 
in Small Cell Lung Cancer 
(SCLC) (Abstract 7LBA)
Elevated DLL3 expression is found in two-thirds of 
SCLC. Rova-T showed superior preclinical anti-tumor 
efﬁcacy over cisplatin/etoposide by targeting DLL3 in 
SCLC. This phase I study assessed single agent Rova-T 
in recurrent SCLC patients with 1 or 2 prior treatments. 
Analysis of 79 patients demonstrated maximum 
tolerated doses (MTD) of 0.2mg/kg Q3Wx3 cycles and 
0.3mg/kg Q6Wx2 cycles, as well as acute and chronic 
DLTs of thrombocytopenia and serosa effusions at 0.8 
and 0.4mg/kg Q3W, respectively. Fatigue, dyspnea, 
nausea and reduced appetite were most common 
emergent adverse events of any grade, while the most 
common treatment related emergent SAEs were serosal 
effusions and thrombocytopenia. Analysis of 29 tumor 
specimens from DLL3-positive patients treated at the 
MTDs demonstrated a partial response of 34% and 
stable disease of 31% (combined clinical beneﬁt rate 
66%). The duration of response among these patients at 
the recommended phase 2 dose of 0.3mg/kg Q6W was 
178+ days, without recurrence. Patients dosed at the 
MTD achieved signiﬁcant response rates in the third-
line setting (no standard care): ORR of 17% in general, 
and 42% in DLL3-positive patients. The results suggest 
signiﬁcant anti-tumor activity and duration of response, 
with manageable safety proﬁle for Rova-T as a single 
agent in patients with recurrent DLL3-positive SCLC.
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•	 TPPA Update
We are all becoming knowledgeable about the TPPA 
and this column has covered this topic no less than 
four times in the past. It is getting exciting now. As 
we recall, the Trans Paciﬁc Partnership Agreement is 
a trade treaty under negotiation between a number of 
countries, it has been negotiated much in secret and has 
been quite controversial. The negotiations prompted a 
degree of turmoil in the US where Senate Democrats 
voted to block a bill that was to give President Obama 
the ability to continue to negotiate in secret, ostensibly 
to keep things manageable and on track. Negotiations 
continued and have just been concluded. The conclusion 
was announced on October 4 and is neatly summarized 
on the Ofﬁce of the United States Trade Representative 
website1. It’s funny to think that a trade negotiation 
summary could be exciting but this one is. As you scroll 
down the page, there are Key Features, Scope, Regional 
Rules (Investment, Cross Border Trade, Phytosanitary 
Measures (??), Electronic Commerce) and right at the 
bottom, second-last heading, there are Exceptions. 
And in that paragraph are the magic words: “A Party 
may elect to deny the benefits of Investor-State dispute 
settlement with respect to a claim challenging a tobacco 
control measure of the Party.” As Reuters reports2, 
this has resulted from much effort and commitment. 
Australia has pushed for tobacco to be exempt and 
United States Congressmen wrote to the US trade 
representative, urging to him to ensure that tobacco 
disputes remain exempt from the TPPA. And in case 
the exemption of tobacco from the TPPA seems just 
too sensible and just too likely for comment, it is worth 
reading an article from the American Journal of Law 
and Medicine3 that outlines (in 2013) the possible 
implications of the TPPA for tobacco control and where 
it could have gone (and might still, depending on 
lobbying and furious protest) horribly wrong. But let’s 
enjoy a victory while we have one. Congratulations to 
the tobacco control community, at least for a little while.
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•	 E-cigarettes (for the uninitiated) leads quickly to the chemistry 
literature and, therefore, confusion but it seems clear 
that free-base nicotine (like free-base cocaine) is rapidly 
absorbed; free-base nicotine in oral spray has been 
shown to increase smoking cessation, at least in the short 
to medium term, when added to patches8. So what does 
all this mean? Well, when all else fails, a look at the 
cellular level might be helpful. A recent paper from the 
American Journal of Physiology Lung Cell Molecular 
Physiology looks at the effect of e-cigarette extracts on 
lung endothelial injury associates soluble components 
of e-cigarette solutions with loss of lung endothelial 
barrier function, oxidative stress and inflammation (Am 
J Physiol Lung Cell Mol Physiol 2015;309(2):L175-87.) 
And lastly, under the heading “Electronic cigarettes: 
not all good news”, the journal is calling for papers 
addressing the mechanisms and potentially toxic effects 
of e-cigarettes, effective between August 1 2015 and 
October 1 2017. A space to watch.
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Just when you think you are out, they pull you back in. We cannot 
avoid this debate and there are plenty of reports this month on 
e-cigarettes. As we recall, Public Health England published an 
update on e-cigarettes4 in August that was fairly supportive of their 
role in tobacco cessation. Despite this, reports continue to appear 
on studies that again question the efﬁcacy and safety of e-cigarettes. 
Bel Marra Health highlights a series of studies that explore the 
issue5. Firstly, a series of papers in Nicotine and Tobacco Research 
(Vol 17 Issue 10) looks at “complexities and controversies”, trends 
in use, device preference and chemical composition. The editorialist 
for the series writes, as in the press release, “it is not surprising that 
the general public is confused, uninformed, of misinformed about 
e-cigarettes”. The press release6 includes some summary statements, 
the most interesting of which are:
“Many state and local smoke-free laws predate the development 
of electronic cigarettes”
“The young people in this study’s focus groups….did not 
perceive that e-cigarettes are effective for smoking cessation”
“Between 2012 and 2013, e-cigarette sales in the tracked 
channels of this study more than doubled, increasing by 132.5% 
across all markets”
“This study analyzed……the chemical composition …in 36 
e-liquids brands from 4 manufacturers. Three-quarters of the 
products contained lower measured nicotine levels than the stated 
label values.”
Another paper along the same theme comes from Chemical 
Research in Toxicology and looks at the type of nicotine in 
electronic cigarette liquids and aerosols7. This study employs an 
extraction method that determines nicotine components by gas 
chromatography and identiﬁes a predominance of the free-base 
form. Searching around for more information on free-base nicotine 
